Rheumatoid Arthritis: Types, risk factors and Laboratory Biomarkers
International Journal of Pathology and Biomarkers · 04.01.2026 · 2 (1) · 1-8
DOI: 10.71428/ijpb.2026.0101 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pathology and Biomarkers, online erschienen am 04.01.2026. Verfasst von Ahmed Yameny.
Abstract (Originalsprache)
Background
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized by persistent synovial inflammation, progressive joint destruction, and extra-articular manifestations. Laboratory biomarkers play a pivotal role in confirming diagnosis, stratifying disease severity, predicting prognosis, and monitoring therapeutic response.
Objectives
This review summarizes the diagnostic, prognostic, and monitoring value of established and emerging laboratory biomarkers in RA, highlighting their clinical utility and limitations.
Methods
Electronic databases, including PubMed, Scopus, and Web of Science, were systematically searched for studies evaluating biomarkers in RA. Biomarkers were categorized into serological (RF, anti-CCP, anti-MCV, anti-CarP), inflammatory (ESR, CRP, calprotectin), and emerging molecular markers (14-3-3η, MMP-3, cytokine panels, and lipid/metabolic profiles). Data on sensitivity, specificity, predictive value, and clinical correlations were extracted.
Results
Rheumatoid arthritis (RA) types are Seropositive RA, Seronegative RA, Early RA, and Established RA. RA risk factors are Genetic Factors, such as the HLA-DRB1 gene, Environmental and Lifestyle Factors, including (1) Cigarette smoking, (2) Infections, (3) Dietary factors, (4) Hormonal influences, and (5) Obesity/Metabolic syndrome. Laboratory Biomarkers: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies remain the most reliable diagnostic markers, with anti-CCP offering superior specificity (~95–98%). Acute-phase reactants such as ESR and CRP correlate with disease activity and therapeutic response but lack diagnostic specificity. Novel biomarkers, including 14-3-3η protein, anti-CarP antibodies, and MMP-3, demonstrate potential for early detection and prognostication, especially in seronegative patients. Multi-biomarker panels integrating serological and molecular data enhance diagnostic accuracy.
Zitieren
APA
Yameny, A. (2026). Rheumatoid Arthritis: Types, risk factors and Laboratory Biomarkers. International Journal of Pathology and Biomarkers, 2(1), 1-8. https://doi.org/10.71428/ijpb.2026.0101
Vancouver
Yameny A. Rheumatoid Arthritis: Types, risk factors and Laboratory Biomarkers. International Journal of Pathology and Biomarkers. 2026;2(1):1-8. doi:10.71428/ijpb.2026.0101
BibTeX
@article{Yameny2026,
author = {Yameny, Ahmed},
title = {Rheumatoid Arthritis: Types, risk factors and Laboratory Biomarkers},
journal = {International Journal of Pathology and Biomarkers},
year = {2026},
volume = {2},
number = {1},
pages = {1--8},
doi = {10.71428/ijpb.2026.0101}
}
EUVIMED